AREXVY (GlaxoSmithKline Australia Pty Ltd)
Product name
AREXVY
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Registration type
EOI
Indication
AREXVY is indicated for active immunisation of individuals for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in:
- adults 50 through 59 years of age who are at increased risk for RSV disease.
The use of this vaccine should be in accordance with official recommendations.